GlassScriptPhysician profile
Emily Sikking
NPI 1780632984
$70,135.19
in general payments reported to CMS, 2019-2025
40 companies · $427 in 2025
The $427 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $1,791 · 2021: $2,116 · 2022: $645 · 2023: $329 · 2024: $182 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $47,548.37 | 2019 | |
| Lupin INC. | $13,211.65 | 2019-2021 | |
| Therapeuticsmd, INC. | $4,481.44 | 2019-2022 | |
| Scynexis, INC. | $1,426.17 | 2021-2022 | |
| Abbvie INC. | $810.60 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $200.12 | 2021-2025 | |
| Exeltis, USA INC. | $193.88 | 2021-2025 | Slynd |
| Evofem Biosciences, INC. | $178.80 | 2021-2025 | Solosec, Phexxi, Phexx |
| Pfizer INC. | $173.77 | 2022-2023 | |
| Valeritas, INC. | $172.65 | 2019 | |
| Aspira Women'S Health INC | $172.64 | 2021-2024 | Ova1 |
| Merck Sharp & Dohme LLC | $150.82 | 2019 | |
| Agile Therapeutics, INC. | $125.21 | 2021-2024 | Twirla |
| Novo Nordisk INC | $111.49 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Sikking listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.